Sunday, December 17, 2023 7:52:09 PM
learningcurve2020,
Name calling becomes you!; ). I agree there is no other company EVER to bring a platform treatment for all solid tumor cancers forward with solid evidence that it is truly tissue agnostic and keep everything in house by building their own CDMOs to produce and develop a final commercial scale product. If you recall there are patents that these companies worked together to develop commercial scale processes and this created stronger patent protections which would be important for anyone considering a merger or buyout.
Now if you really want to be an influencer why not spend your time working on a cancer cure of your own and begin by focusing on your CDMO facility first so that you don’t go broke while trying to do so. Maybe that’s the shorter path to success so why don’t you try it. In the mean time, who is the great success story, like NWBO will be with tissue agnostic platform tech for all solid tumor cancers, that you have as an example that has done this by starting first with their own CDMO(s)?; ). I think there will be lots of chirping by the crickets or wolves howling at the moon with this one ; ). Best wishes.
Name calling becomes you!; ). I agree there is no other company EVER to bring a platform treatment for all solid tumor cancers forward with solid evidence that it is truly tissue agnostic and keep everything in house by building their own CDMOs to produce and develop a final commercial scale product. If you recall there are patents that these companies worked together to develop commercial scale processes and this created stronger patent protections which would be important for anyone considering a merger or buyout.
Now if you really want to be an influencer why not spend your time working on a cancer cure of your own and begin by focusing on your CDMO facility first so that you don’t go broke while trying to do so. Maybe that’s the shorter path to success so why don’t you try it. In the mean time, who is the great success story, like NWBO will be with tissue agnostic platform tech for all solid tumor cancers, that you have as an example that has done this by starting first with their own CDMO(s)?; ). I think there will be lots of chirping by the crickets or wolves howling at the moon with this one ; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
